MedTech
Forging a path for MedTech Innovation.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology & Hematology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI®
-
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESBlog
Molecular Diagnostics in 2025
Resilience, Recovery, and What’s Next
May 22, 2025
The molecular diagnostics (MDx) landscape continues to evolve rapidly, shaped by the aftershocks of the COVID-19 pandemic and a renewed focus on broader infectious disease testing. At IQVIA MedTech, we recently presented our latest findings at AMP 2025 Analyst Day, highlighting the shifts, challenges, and opportunities shaping the molecular market today—and what lies ahead.
Beyond COVID: A Return to Growth
While COVID-19 revenues declined significantly in 2024, the broader molecular market proved its resilience, posting high single-digit growth when excluding COVID-related testing. This rebound has pushed market performance above pre-pandemic levels, signalling strong recovery and renewed investment across key diagnostic segments.
The Rise of the "Quademic"
In the U.S., what began as a "tripledemic"—with simultaneous surges in influenza, RSV, and COVID—has now evolved into a "quademic" with the resurgence of Norovirus. Despite being a gastrointestinal bug, its inclusion is due to being a winter pathogen that affects many of the same patients. Perhaps most notably, flu-related deaths surpassed those from COVID for the first time since the pandemic, marking the highest rates in 15 years. These epidemiological shifts are driving renewed demand for multiplex respiratory panels and stressing the importance of pandemic preparedness infrastructure.
These shifts are not just a coincidence—it’s a consequence of immunity debt.
During the height of the pandemic, reduced exposure to common respiratory and gastrointestinal pathogens (due to masking, lockdowns, and social distancing) led to a population-wide decline in baseline immunity. Now, as normal interactions resume, individuals—especially children and the elderly—are experiencing more intense and frequent infections from viruses they previously encountered with less severity.
A Changing Competitive Landscape
While COVID revenue declines affected top-line performance, all major industry players demonstrated healthy ex-COVID growth ranging from +3% to +20%. This broad-based recovery reflects strategic realignments, portfolio expansions, and new platform introductions—especially in STI, respiratory, and AMR-related testing.
Key Trends Shaping the Market
- STIs Take the Lead: For the second straight year, sexually transmitted infection (STI) diagnostics have overtaken Core Viro (defined as HIV-Hepatitis) as the largest non-respiratory molecular segment, driven by rising incidence and initiatives aimed at screening to control spread.
- Instrument Placement Challenges Persist: Although new instrument placements are improving, the post-pandemic environment continues to pose logistical and operational hurdles.
- HPV Screening Reimagined: New guidelines now recommend HPV DNA testing over the traditional Pap smear for cervical cancer screening. The inclusion of self-collected specimens is important for accessibility and population screening.
- Point-of-Care (POC) Expansion: The NAT POC segment is expanding beyond respiratory infections. In early 2025, Roche received FDA clearance and CLIA waiver for cobas® liat CTNG & CTNG/MG, while bioMérieux is making notable progress with its Spotfire platform. In addition, several other competitors also have POC solutions in the pipeline.
- Antimicrobial Resistance (AMR) in the Spotlight: With projections estimating 10 million deaths annually and $100 trillion in global economic impact by 2050, AMR is becoming a critical focus. This urgency is accelerating demand for multiplex panels and flexible testing options, even amid reimbursement challenges.
What’s Next in Molecular Diagnostics
As we look ahead, three forces are set to shape the future of molecular diagnostics:
- Continued POC Innovation: Expansion into STIs, AMR, and gastrointestinal pathogens.
- Smarter Testing Strategies: Shift toward smaller, flexibly reimbursable panels tailored to clinical need.
- Global Health Preparedness: Strengthened surveillance and rapid response testing for emerging infectious threats.
The molecular diagnostics sector has shown not just resilience, but a remarkable capacity for reinvention. As we navigate a post-pandemic era marked by new clinical priorities and shifting epidemiology, one thing is clear: molecular testing will continue to be a cornerstone of modern healthcare—and IQVIA MedTech is here to guide the way forward.
For more insights into our IVD market intelligence or to schedule a custom briefing, reach out to our team today by clicking the CONTACT US button.
Related solutions
Commercial Solutions
Connected commercial solutions, maximizing market performance.